BOUCHERVILLE, QC, Dec. 18, 2024 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB) ("the Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical Corporation, is pleased to announce the acquisition of Dermolab Pharma Ltd. ("Dermolab"), a contract manufacturing company specializing in the manufacturing of liquid, and semi-solid products, based in Ste-Julie, Quebec. This acquisition increases LSL Pharma's contract development and manufacturing activities, while creating synergies with its other subsidiaries, LSL Laboratory Inc., Steri-Med Pharma Inc. and Virage Santé Inc. LSL Pharma also announced the closing of a $2 million concurrent debt financing (the "Financing"). The closing of the transaction occurred after markets had closed on December 17, 2024.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
